EGFR and MET belong to members of the RTK family, and MET, the tyrosine kinase transmembrane receptor for MET, is a protein product encoded by the c-MET proto oncogene that has been of interest in the clinic as a potential therapeutic target in multiple tumor types [48]. This evidence concerns the gene MET and neoplasm.